Drug Trial Radar · NCT06750094
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Dec 12, 2024
Primary completion
Dec 15, 2027
Study completion Apr 13, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
Conditions
- Colorectal Neoplasms
Interventions
AmivantamabBiological
Amivantamab will be administered.
CetuximabBiological
Cetuximab will be administered.
BevacizumabBiological
Bevacizumab will be administered.
5-fluorouracilDrug
5-fluorouracil will be administered as chemotherapy regimen.
Leucovorin calcium/LevoleucovorinDrug
Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
IrinotecanDrug
Irinotecan will be administered as chemotherapy regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 2 years 1 month
- Overall Survival (OS)Time frame: Up to 4 years 4 months
Locations
251 sites in 26 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Center
Chandler, Arizona · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Arizona Oncology Associates PC NAHOA
Prescott, Arizona · Completed
St. Bernard's Medical Center
Jonesboro, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
CBCC Global Research
Bakersfield, California · Recruiting
Los Angeles Cancer Network
Glendale, California · Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA
Santa Monica, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
Torrance Memorial Physicians Network
Torrance, California · Recruiting
University of Colorado Denver Anschultz Medical Campus
Aurora, Colorado · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Eastern Connecticut Hematology & Oncology Assoc.
Norwich, Connecticut · Completed
Florida Cancer Specialists South
Fort Myers, Florida · Recruiting
Mount Sinai Medical Center Campus
Miami Beach, Florida · Completed
AdventHealth Cancer Institute
Orlando, Florida · Recruiting
Florida Cancer Specialists North Region
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists East
West Palm Beach, Florida · Recruiting
University Cancer And Blood Center LLC
Athens, Georgia · Recruiting
Grady Memorial Hospital
Atlanta, Georgia · Recruiting
Piedmont Cancer Institute
Atlanta, Georgia · Recruiting
Winship Cancer Institute Emory University
Atlanta, Georgia · Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Illinois CancerCare
Peoria, Illinois · Recruiting
Franciscan Health
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Mission Cancer Blood
Waukee, Iowa · Recruiting
Cancer Center of Kansas
Wichita, Kansas · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
MedStar Franklin Square Medical Center
Baltimore, Maryland · Recruiting
Frederick Health Hospital - James M Stockman Cancer Institute
Frederick, Maryland · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Cancer And Hematology Centers of Western Michigan PC
Grand Rapids, Michigan · Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi · Recruiting
Washington University School Of Medicine
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Showing 40 of 251 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.